Previous 10 |
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Genmab ( GNMSF ) and their par...
Karyopharm Therapeutics (NASDAQ: KPTI ) has issued an additional $22.5M aggregate principal amount of 3.00% convertible senior notes due 2025 pursuant to the exercise in full of the option to purchase additional notes granted to the initial purchasers in previously announced private offeri...
NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
2024-08-06 22:30:18 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q2 2024 Earnings Call Aug 06, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q2 2024 Earnings C...
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million ; Positive Momentum e...
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...